«Previous Article|Table of Contents|Next Article»

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:

2024 01

Page:

93-95

Research Field:

Publishing date:

Info

Title:

Expression and clinical significance of S1PR1 in gastric cancer tissues

Author(s):

LIU Jiameng¹; LI Ming²

1.Gusu School,Nanjing Medical University,Jiangsu Nanjing 211166,China;2.Department of Pathology,the Affiliated Suzhou Hospital of Nanjing Medical University,Suzhou Municipal Hospital,Jiangsu Suzhou 215002,China.

Keywords:

S1PR1; gastric cancer; immunohistochemistry; clinicopathological features

PACS:

R735.2

DOI:

10.3969/j.issn.1672-4992.2024.01.016

Abstract:

Objective:To investigate the expression of sphingosine-1-phosphate receptor 1 (S1PR1) and its clinical significance in gastric cancer tissues.Methods:A retrospective analysis was conducted on 328 gastric cancer patients with complete clinicopathological data.The expression of S1PR1 was detected by immunohistochemistry and its relationship with the clinicopathological features and prognosis of gastric cancer was analyzed.Results:The positive rate of S1PR1 in clinical stage I+II tissues was 55.3%,while it was 70.2% in tissues from clinical stage III+IV.The difference was statistically significant (P£¼0.05).There were statistically significant differences in S1PR1 expression between gastric cancer patients with lymph node metastasis and tumor size(P£¼0.05),but no statistically significant differences with age,gender,tumor differentiation,and Lauren classification.The overall survival time of S1PR1 positive expression patients was shorter than that of negative expression patients,and the difference was statistically significant (P£¼0.05).The expression of S1PR1 in gastric cancer tissues was significantly higher than that in adjacent tissues (P£¼0.05).Conclusion:The expression of S1PR1 is closely related to the clinical stage and lymph node metastasis of gastric cancer patients,and S1PR1 positive expression is associated with poor prognosis.These findings provide new insights for the future treatment of gastric cancer.

References:

£Û1£Ý SUNG H,FERLAY J,SIEGEL RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries£ÛJ£Ý.CA Cancer J Clin,2021,71(3):209-249.
£Û2£ÝZENG Y,JIN RU.Molecular pathogenesis,targeted therapies,and future perspectives for gastric cancer£ÛJ£Ý.Semin Cancer Biol£¬2022£¬86(Pt3):566-582.
£Û3£Ý LIU S,NI C,ZHANG D,et al.S1PR1 regulates the switch of two angiogenic modes by VE-cadherin phosphorylation in breast cancer£ÛJ£Ý.Cell Death & Disease,2019,10(3):200.
£Û4£Ý ZHONG L,XIE L,YANG Z,et al.Prognostic value of S1PR1 and its correlation with immune infiltrates in breast and lung cancers£ÛJ£Ý.BMC Cancer,2020,20(1):766.
£Û5£Ý LIANG J,NAGAHASHI M,KIM EY,et al.Sphingosine-1-phosphate links persistent STAT3 activation,chronic intestinal inflammation,and development of colitis-associated cancer£ÛJ£Ý.Cancer Cell,2013,23(1):107-120.
£Û6£Ý AHN JH,KIM TJ,LEE JH,et al.Mutant p53 stimulates cell invasion through an interaction with Rad21 in human ovarian cancer cells£ÛJ£Ý.Scientific Reports,2017,7(1):9076.
£Û7£Ý ALSINA M,ARRAZUBI V,DIEZ M,et al.Current developments in gastric cancer:from molecular profiling to treatment strategy£ÛJ£Ý.Nat Rev Gastroenterol Hepatol£¬2023,20(3):155-170.
£Û8£Ý LEI ZN,TENG QX,TIAN Q,et al.Signaling pathways and therapeutic interventions in gastric cancer£ÛJ£Ý.Signal Transduct Target Ther£¬2022£¬7(1):358.
£Û9£Ý WEICHAND B,POPP R,DZIUMBLA S,et al.S1PR1 on tumor-associated macrophages promotes lymphangiogenesis and metastasis via NLRP3/IL-1¦Â£ÛJ£Ý.Journal of Experimental Medicine,2017,214(9):2695-2713.
£Û10£ÝCHEN H,WANG J,ZHANG C,et al.Sphingosine 1-phosphate receptor,a new therape-utic direction in different diseases£ÛJ£Ý.Biomed Pharmacother£¬2022,153:113341.
£Û11£Ý ROSTAMI N,NIKKHOO A,AJJOOLABADY A,et al.S1PR1 as a novel promising therapeutic target in cancer therapy£ÛJ£Ý.Molecular Diagnosis & Therapy,2019,23(4):467-487.
£Û12£Ý ZHENG H,SIDDHARTH S,PARIDA S,et al.Tumor microenvironment:Key players in triple negative breast cancer immunomodulation£ÛJ£Ý.Cancers,2021,13(13):3357.
£Û13£Ý GO H,KIM PJ,JEON YK,et al.Sphingosine-1-phosphate receptor 1 (S1PR1) expression in non-muscle invasive urothelial carcinoma£ºAssociation with poor clinical outcome and potential therapeutic target£ÛJ£Ý.European Journal of Cancer,2015,51(14):1937-1945.
£Û14£Ý ZHU Y,LUO G,JIANG B,et al.Apolipoprotein M promotes proliferation and invasion in non-small cell lung cancers via upregulating S1PR1 and activating the ERK1/2 and PI3K/AKT signaling pathways£ÛJ£Ý.Biochemical and Biophysical Research Communications,2018,501(2):520-526.
£Û15£Ý YOU X,WANG Y,WU J,et al.Galectin-1 promotes metastasis in gastric cancer through a sphingosine-1-phosphate receptor 1-dependent mechanism£ÛJ£Ý.Cellular Physiology and Biochemistry,2018,51(1):11-30.
£Û16£Ý ZHOU Y,GUO F.A selective sphingosine-1-phosphate receptor 1 agonist SEW-2871 aggravates gastric cancer by recruiting myeloid-derived suppressor cells£ÛJ£Ý.Journal of Biochemistry,2018,163(1):77-83.
£Û17£Ý NAGAHASHI M,YAMADA A,KATSUTA E,et al.Targeting the SphK1/S1P/S1PR1 axis that links obesity,chronic inflammation,and breast cancer metastasis£ÛJ£Ý.Cancer Research,2018,78(7):1713-1725.
£Û18£Ý LIN Q,WEI Y,ZHONG Y,et al.Aberrant expression of sphingosine-1-phosphate receptor 1 correlates with metachronous liver metastasis and poor prognosis in colorectal cancer£ÛJ£Ý.Tumor Biology,2014,35(10):9743-9750.
£Û19£Ý BIEN-M¦ZLLER S,LANGE S,HOLM T,et al.Expression of S1P metabolizing enzymes and receptors correlate with survival time and regulate cell migration in glioblastoma multiforme£ÛJ£Ý.Oncotarget,2016,7(11):13031-13046.

Memo

Memo:

½­ËÕÊ¡ËÕÖÝÊÐÎÀÉú¿Æ¼¼´´ÐÂÏîÄ¿£¨±àºÅ£ºSKYD2022134£©

Common functions

Last Update: 2023-11-30